Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tao Synergies Inc.

8.50
+0.42005.20%
Post-market: 8.28-0.2200-2.59%16:58 EDT
Volume:140.22K
Turnover:1.13M
Market Cap:11.81M
PE:-0.86
High:8.53
Open:7.88
Low:7.60
Close:8.08
Loading ...

Company Profile

Company Name:
Tao Synergies Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
4
Office Location:
1185 Avenue of the Americas,3rd Floor,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.

Directors

Name
Position
Joshua Silverman
Executive Chairman of the Board
William S. Singer
Vice Chairman of the Board
Alan J. Tuchmam
Chief Medical Officer,Director
Bruce T. Bernstein
Independent Director
Jonathan L. Schechter
Independent Director

Shareholders

Name
Position
Robert Weinstein
Chief Financial Officer, Secretary and Executive Vice President
Alan J. Tuchmam
Chief Medical Officer,Director
Joshua Silverman
Executive Chairman of the Board